You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

PLATINOL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Platinol, and what generic alternatives are available?

Platinol is a drug marketed by Hq Spclt Pharma and is included in one NDA.

The generic ingredient in PLATINOL is cisplatin. There are fourteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cisplatin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Platinol

A generic version of PLATINOL was approved as cisplatin by PHARMACHEMIE BV on May 16th, 2000.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PLATINOL?
  • What are the global sales for PLATINOL?
  • What is Average Wholesale Price for PLATINOL?
Summary for PLATINOL
US Patents:0
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 343
DailyMed Link:PLATINOL at DailyMed
Drug patent expirations by year for PLATINOL
Recent Clinical Trials for PLATINOL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Regeneron PharmaceuticalsPhase 2
AstraZenecaPhase 3
Wuhan Union Hospital, ChinaPhase 2

See all PLATINOL clinical trials

Pharmacology for PLATINOL

US Patents and Regulatory Information for PLATINOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hq Spclt Pharma PLATINOL cisplatin INJECTABLE;INJECTION 018057-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Hq Spclt Pharma PLATINOL-AQ cisplatin INJECTABLE;INJECTION 018057-003 Jul 18, 1984 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PLATINOL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Hq Spclt Pharma PLATINOL cisplatin INJECTABLE;INJECTION 018057-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Hq Spclt Pharma PLATINOL cisplatin INJECTABLE;INJECTION 018057-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PLATINOL

See the table below for patents covering PLATINOL around the world.

Country Patent Number Title Estimated Expiration
German Democratic Republic 142293 VERFAHREN ZUR HERSTELLUNG EINES PHARMAZEUTISCHEN MITTELS ⤷  Sign Up
Sweden 445172 STABIL, STERIL VATTENLOSNING AV CISPLATIN I ENHETSDOSERINGSFORM ⤷  Sign Up
Sweden 7900774 ⤷  Sign Up
Israel 56540 PHARMACEUTICAL COMPOSITIONS CONSISTING OF A STABLE AQUEOUS SOLUTION OF A PLATINUM COMPLEX SALT ⤷  Sign Up
Ireland 790194 ⤷  Sign Up
Ireland 48177 PHARMACEUTICAL FORMULATIONS CONTAINING CIS-PLATINUM(II)DIAMMINEDICHLORIDE ⤷  Sign Up
Spain 478272 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.